What is the 13F Pro Quality Score for XNCR?

13F Pro ranks Xencor Inc (XNCR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XNCR's current score at https://13fpro.ai/research/XNCR (free sign-up required for the full ranking).

Which hedge funds own the most XNCR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XNCR include BlackRock,, PRIMECAP MANAGEMENT CO/CA/, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/XNCR as soon as new 13F filings post.

Where does 13F Pro source XNCR data?

All Xencor Inc fundamentals and ownership data come directly from SEC EDGAR. Xencor Inc files with the SEC under CIK 1326732. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XNCR in?

Xencor Inc (XNCR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XNCR research updated on 13F Pro?

XNCR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Xencor Inc(XNCR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1326732 XNCR stock profile & AI dashboard →

13F Pro Quality Score

13.1/100

Rank #2,773 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

8.9/100

Profitability

5.2/100

Balance Sheet

9.6/100

Earnings Quality

30.0/100

Free Cash Flow

5.6/100

Institutional Flow

71.4/100

Revenue Scale

17.7/100

Dilution Risk

5.8/100

XNCR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Xencor Inc (XNCR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XNCR at 13.1/100 on a 32-signal composite quality model, placing it at rank #2,773 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (5.2) and free cash flow (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Xencor Inc reports quarterly revenue of $4.5M, net income of $-128.9M, free cash flow of $-68.2M. Top institutional holders of XNCR by reported 13-F value include BlackRock,, PRIMECAP MANAGEMENT CO/CA/, BVF /IL, based on the most recent SEC filings. XNCR trades on the Nasdaq exchange and files with the SEC under CIK 1326732. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XNCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xencor Inc directly from SEC EDGAR. Xencor Inc's 13F Pro composite quality score has ranged between 8 and 57 since 2021, currently 13.1 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Xencor Inc

Quirks, history, and lore behind XNCR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue in the low tens of millions, typical of a clinical-stage biotech — the real value is in the pipeline, not the income statement.
3
The History
Founded in the early 2000s, it was built around a proprietary protein engineering platform designed to make antibody drugs work better and last longer.
4
The Secret
Its core trick is Fc engineering — tweaking the non-binding end of an antibody to dial up efficacy, tune immune responses, or extend half-life in the body.
5
The Lore
It has struck licensing deals with multiple large pharma companies who want its engineering technology baked into their own antibody programs, making it a quiet behind-the-scenes force in biotech.
6
The Giveaway
The company's very name is a mashup of "Xen" and "core" — and its ticker is basically just the consonants, because apparently vowels are overrated.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$4.5M

Net Income

Q1 2026

$-128.9M

Free Cash Flow

Q1 2026

$-68.2M

D/E Ratio

Q1 2026

0.21

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-28.1% YoY

$125.6MFY 2025

FY21 $275.1MFY22 $164.6MFY23 $174.6MFY25 $125.6M

Net Income

+31.0% YoY

$-91.9MFY 2025

FY21 $82.6MFY22 $-55.2MFY23 $-133.1MFY25 $-91.9M

Operating Income

-34.1% YoY

$-177.5MFY 2025

FY21 $43.8MFY22 $-82.5MFY23 $-132.4MFY25 $-177.5M

EPS (Diluted)

+43.6% YoY

$-1.24FY 2025

FY21 $1.37FY22 $-0.93FY23 $-2.20FY25 $-1.24

Total Assets

-9.3% YoY

$875.5MFY 2025

FY21 $838.2MFY22 $846.3MFY23 $965.1MFY25 $875.5M

Total Debt

+470.9% YoY

$119.7MFY 2025

FY21 —FY22 $0.00FY23 $21.0MFY25 $119.7M

Op. Cash Flow

-73.4% YoY

$-135.1MFY 2025

FY21 $-16.9MFY22 $24.5MFY23 $-77.9MFY25 $-135.1M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019	FY 2017
Revenue	$125.6M -28.1%	$174.6M +6.1%	$164.6M -40.2%	$275.1M +75.6%	$156.7M +239.5%	$46.1M
Net Income	$-91.9M +31.0%	$-133.1M -141.3%	$-55.2M -166.8%	$82.6M +207.5%	$26.9M +169.8%	$-38.5M
Operating Income	$-177.5M -34.1%	$-132.4M -60.5%	$-82.5M -288.4%	$43.8M +216.6%	$13.8M +132.1%	$-43.1M
EPS (Diluted)	$-1.24 +43.6%	$-2.20 -136.6%	$-0.93 -167.9%	$1.37 +197.8%	$0.46 +156.1%	$-0.82
Total Assets	$875.5M -9.3%	$965.1M +14.0%	$846.3M +1.0%	$838.2M +25.1%	$670.3M +71.8%	$390.2M
Total Debt	$119.7M +470.9%	$21.0M	$0.00	—	—	—
Operating Cash Flow	$-135.1M -73.4%	$-77.9M -418.3%	$24.5M +245.3%	$-16.9M -126.2%	$64.4M +291.6%	$-33.6M

AI Insight: XNCR Financial Trends

A $129M net loss in Q1 2026 — the largest in eight quarters — signals a sharp deterioration driven by a revenue collapse to just $5M.

• Revenue fell from $44M in Q2 2025 to $5M in Q1 2026, the lowest level in the observed period.

• Net loss widened dramatically to $129M in Q1 2026 from $7M in Q4 2025, reversing a prior improving trend.

• Total debt has declined steadily from $164M in Q4 2024 to $109M in Q1 2026, reducing leverage incrementally.

• Operating cash outflow deepened to $68M in Q1 2026, the worst since Q2 2024's $64M burn.

⚠ Equity eroded sharply from $636M in Q4 2025 to $516M in Q1 2026 — a $120M single-quarter decline.

⚠ Revenue at $5M in Q1 2026 vs. $28M–$53M range in prior quarters; sustainability of royalty/milestone income is a key risk.

⚠ Operating losses widened to $78M in Q1 2026 despite earlier signs of improvement; cost discipline warrants close monitoring.

AI Insight: XNCR Ratio Trends

Q1 2026 ROE and ROA collapsed to -100.0% and -70.0%, reversing a brief stabilization seen in Q3–Q4 2025.

• ROE deteriorated sharply from -4.2% in Q4 2025 to -100.0% in Q1 2026, signaling a severe one-quarter earnings shock.

• ROIC has worsened consecutively from -25.1% in Q3 2025 to -28.4% in Q4 2025 and -49.9% in Q1 2026.

• D/E ratio remained relatively contained, ranging 0.19–0.24 since Q4 2024, suggesting limited debt financing pressure.

• OpMargin swung from -25.0% in Q4 2024 to -189.9% in Q4 2025, reflecting highly volatile operating results quarter to quarter.

⚠ ROE and ROA plunging to -100.0% and -70.0% in Q1 2026 after near-zero readings in Q3–Q4 2025 warrants close monitoring.

⚠ Repeated OpMargin gaps (Q2 2024, Q3 2025, Q1 2026) limit trend visibility; next reported figure will be critical.

⚠ TTM NPM of -177.1% versus Q4 2025's -23.6% suggests a large one-off item is distorting the trailing picture.

Get alerted when XNCR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Xencor Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XNCR

BlackRock, Inc.
$157.2M13,035,918 sh
PRIMECAP MANAGEMENT CO/CA/
$124.7M10,338,022 sh
BVF INC/IL
$86.0M7,133,720 sh
RTW INVESTMENTS, LP
$81.7M6,777,461 sh
RA CAPITAL MANAGEMENT, L.P.
$59.1M4,897,237 sh
STATE STREET CORP
$52.5M4,352,036 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$42.2M3,500,342 sh
VANGUARD CAPITAL MANAGEMENT LLC
$37.4M3,101,647 sh
TCG Crossover Management, LLC
$29.6M2,452,138 sh
EcoR1 Capital, LLC
$26.3M2,183,000 sh

Fund	Value	Shares
BlackRock, Inc.	$157.2M	13,035,918
PRIMECAP MANAGEMENT CO/CA/	$124.7M	10,338,022
BVF INC/IL	$86.0M	7,133,720
RTW INVESTMENTS, LP	$81.7M	6,777,461
RA CAPITAL MANAGEMENT, L.P.	$59.1M	4,897,237
STATE STREET CORP	$52.5M	4,352,036
VANGUARD PORTFOLIO MANAGEMENT LLC	$42.2M	3,500,342
VANGUARD CAPITAL MANAGEMENT LLC	$37.4M	3,101,647
TCG Crossover Management, LLC	$29.6M	2,452,138
EcoR1 Capital, LLC	$26.3M	2,183,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XNCR on your watchlist

Track score changes the day Xencor Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XNCR a good stock to buy?

13F Pro's AI-powered analysis of Xencor Inc (XNCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XNCR are available on the XNCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XNCR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XNCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xencor Inc's investment landscape.